Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
This article was originally published in The Pink Sheet Daily
Executive Summary
In the latest round of price cuts announced this week, Pfizer Inc. (combined with Wyeth) took the biggest hit, with 17 products seeing prices slashed.
You may also be interested in...
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health
Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say
SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies